08.06.2016 Views

CPDD 78th Annual Scientific Meeting Program

2016-78th-CPDD-Program-Book-6-07-16FINAL

2016-78th-CPDD-Program-Book-6-07-16FINAL

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Tuesday, June 14<br />

XIII.<br />

WORKSHOPS<br />

Regulatory and methodological considerations in the evaluation of<br />

drug dependence in the preclinical and clinical setting<br />

Chairs: Beatrice Setnik and Michael Klein<br />

Evaluating drug withdrawal effects is an integral component of dependence potential,<br />

which informs the overall safety, appropriate dosing, and scheduling of a drug. The<br />

methodological approaches to assess dependence continue to evolve and require<br />

careful evaluation of both preclinical and clinical data. Physical dependence can<br />

manifest from various drug classes including classes of drugs that are and are not<br />

associated with substance use disorder (e.g. beta blockers, corticosteroids).<br />

Preliminary approaches often include animal models to evaluate psychological<br />

dependence and the physical manifestation of withdrawal type symptoms. Translation<br />

of animal pharmacokinetics to human can be challenging and needs to be carefully<br />

evaluated to determine the translatability of animal to human data. In the clinical<br />

setting, evaluation of withdrawal requires characterization of a drug’s pharmacology to<br />

determine what type of symptoms may manifest upon abrupt discontinuation. Study<br />

populations must be carefully considered, particularly in patient populations that<br />

cannot be safely withdrawn from study drug. Clinical trials must determine what<br />

population, duration of maintenance and endpoints are relevant for a given drug.<br />

Commonly adverse events and drug-specific withdrawal scales are included to evaluate<br />

withdrawal symptoms, however other pharmacodynamics measures may also be<br />

considered. The administration of endpoints and safety monitoring requires also<br />

practical considerations in the context of larger patient trials, where confined stays<br />

may not be possible following abrupt discontinuation. This workshop will address the<br />

regulatory and methodological considerations that are rapidly evolving in this active<br />

area of research and will cover case examples of studies examining drug withdrawal<br />

and dependence.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!